Company ProfilePremium

CORESTEMCHEMON Inc. (formerly CORESTEM Inc.)

Company Profile Analysis

Ticker: 166480.KQ코아스템켐온 주식회사

ESOMAR 23 Corporate BadgeISO Certifications Badge
CORESTEMCHEMON Inc. - Company showcase

Year Founded & Workforce

2003

391 Employees

CORESTEMCHEMON Inc. logo

CORESTEMCHEMON Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

CORESTEMCHEMON Inc. Overview

CorestemChemon is a small-cap Korean biotechnology company that combines two businesses with very different economics under one listed shell. The first is a cell-therapy franchise built around Neuronata-R (lenzumestrocel), an autologous bone-marrow-derived mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis (ALS) that has been sold in Korea since 2015 under a 2014 conditional approval. The second is a non-clinical contract research organisation (CRO), inherited from Chemon, which provides toxicology, pharmacokinetics, safety pharmacology and environmental toxicity testing and generates essentially all current revenue. The company's Phase 3 ALSummit trial missed its primary endpoint in the overall population but showed benefit in slow-progressing patients; Korea's MFDS approved a label modification in May 2026, keeping the product on the market. The investment case now hinges on restarting manufacturing, an FDA Type C meeting and a targeted 2027 US BLA filing, all funded from a thin balance sheet.


Company's own description

In company materials, CorestemChemon describes itself as a "total health care" company with a full drug-development cycle capability — from early non-clinical experiments through Phase 1–3 clinical development — combining a cell-therapy developer/manufacturer with Korea's first private non-clinical CRO [S25][S26]. Its corporate profile describes the biopharmaceuticals division as focused on rare and intractable diseases (ALS, lupus, neuromyelitis optica, multiple system atrophy) and the non-clinical CRO division as offering toxicity studies, pharmacokinetic analysis, safety pharmacology and environmental toxicity testing [S38].

Independent characterisation

In practice, CorestemChemon is a service business funding a single-asset biotech. The CRO division provides recurring (though cyclical) fee-for-service revenue; the biopharmaceutical division has contributed only low single-digit percentages of revenue even when Neuronata-R was in production — 4.41% of revenue (KRW 1.3 bn) in the first nine months of 2023 and KRW 0.6 bn of KRW 15.5 bn in H1 2024 [S31][S30]. Since Q1 2025, Neuronata-R manufacturing has been suspended pending a new manufacturing site certification and the MFDS license modification, so Q2 2026 revenue was 100% non-clinical CRO services [S9][S1].

Revenue model mix

Revenue streamModelWeight (latest disclosed)Notes
Non-clinical CRO servicesProject-based contract research; revenue recognised by percentage of completion~100% of Q2 2026 revenueContract backlog in progress at 30 Jun 2026: KRW 27.15 bn total, of which KRW 14.46 bn already recognised [S8]
Neuronata-R (product sales)Per-patient autologous manufacturing and supply to hospitals~0% since Q1 2025 (production halted)Historically ~4% of revenue [S30][S31]
Licensing / royaltiesNone disclosed0%No out-licensing revenue disclosed
Subscription—0%—

Value-chain position

Cell therapy: vertically integrated — R&D, clinical development, GMP manufacturing (Yongin plant; new Osong plant), and supply. Because the product is autologous, each dose begins with a bone-marrow harvest from the patient, followed by cell culture and intrathecal injection; the product's expiry is 48 hours after manufacture [S42].

CRO: upstream service provider to pharmaceutical, biotech, health-functional-food and cosmetics-ingredient developers, and to government-funded research projects [S8][S9].

Customer types and end-markets

BusinessCustomer typesEnd-markets
Neuronata-RALS patients treated through Korean hospitals; prospectively foreign patients travelling to Korea from 2027 [S17]Rare neurodegenerative disease (ALS/MND)
Non-clinical CROKorean pharma/biotech sponsors; national R&D projects; functional food and cosmetics-material developers [S8][S9]Drug development outsourcing (preclinical)

Strategy

Stated strategic themes (paraphrased from company communications)

  1. Keep Neuronata-R available in Korea and restart supply — the May 2026 MFDS decision is framed as preserving a cell-based option for the patients most likely to benefit, with full-scale production targeted for early 2027 [S17].

  2. Precision positioning in slow-progressing ALS, supported by NfL biomarker data, as the basis for regulatory discussions [S20][S17].

  3. US entry via a staged regulatory path: FDA Type C meeting → RMAT designation → BLA filing targeted for 2027 [S14][S16].

  4. Real-world evidence generation, including treatment of foreign patients travelling to Korea [S17][S18].

  5. CRO recovery and diversification into functional foods, cosmetics materials and next-generation (organoid/transcriptomics) testing [S9][S4b].

Initiatives in the last 24 months

InitiativeDateDetailSource
Phase 3 subgroup strategyMay 2025 onwardSlow-progressor analysis used for MFDS and FDA discussions[S19]
ATG Lifetech partnershipJul 2025Transcriptomics-powered, organoid-based preclinical testing[S4b]
Rights offeringAug–Nov 2025KRW 26.1 bn; debt repayment and working capital[S12][S13]
Osong plant licensingDec 2025 / May 2026Manufacturing licence change; cell processing facility licence[S15]
NSF Piedmont Triad Regenerative Medicine EngineDec 2025First Korean company admitted; US operations moved to North Carolina[S18][S17]
FDA Type C meetingAug 2026Nine discussion items incl. Phase 3 interpretation and BLA strategy[S16]

Medium-term targets / guidance

No quantitative financial guidance is published. Qualitative milestones: Type C meeting expected before end-October 2026; full-scale Neuronata-R production early 2027; US BLA filing in 2027; CRO revenue recovery in H2 2026 [S16][S17][S8]. ESG commitments: not publicly disclosed.

Products & Services

Biopharmaceutical Division

AttributeDetailSource
TypeAutologous bone-marrow-derived mesenchymal stem cell (MSC) therapy[S17]
IndicationSlowing progression of ALS (Lou Gehrig's disease)[S16]
AdministrationIntrathecal injection[S17][S42]
Proposed mechanismParacrine action: anti-inflammatory factors (TGF-β1, IL-4, IL-10) dampening neuroinflammation; neuroprotective factors (VEGF, BDNF, IGF) supporting neuronal survival[S17]
Shelf life48 hours from manufacture; a refrigerated preservative extending storage from 2 to 7 days was tested around 2020[S42][S35]
Regulatory status — KoreaConditional approval 2014; launched Feb 2015; license modification reflecting Phase 3 data approved by MFDS in May 2026, keeping the product on the market[S17][S26]
Regulatory status — US/EUFDA Orphan Drug (2018); EMA Orphan Drug (2019); FDA Type C meeting requested Aug 2026; BLA targeted for 2027[S17][S16]
Patients treatedMore than 400 in Korea[S17][S21]
ManufacturingYongin GMP plant (utilisation 16.8% in 2024, 1.4% in 2025); new Osong plant licensed Dec 2025 (manufacturing change) and May 2026 (cell processing facility)[S9][S15]
Supply statusProduction suspended since Q1 2025; full-scale production expected early 2027[S9][S17]
PricingNot publicly disclosed. The company sought national health insurance listing via price negotiation around 2018[S43]

(a) Neuronata-R® Inj. (lenzumestrocel) — commercial (Korea)

Clinical evidence summary

Phase 2 (NCT01363401): 64 participants, 1:1 randomised; two injections slowed ALSFRS-R decline versus control for at least six months [S21][S42].

Phase 3 ALSummit (NCT04745299): double-blind, randomised, placebo-controlled, multicentre; 115 participants; three arms (two Neuronata-R injections followed by three placebo injections; five Neuronata-R injections; five placebo injections) [S21][S42]. Primary endpoint CAFS (Combined Assessment of Function and Survival) was not met in the intent-to-treat population [S21]. In the slow-progressor subgroup, the therapy met CAFS and the ALSFRS-R secondary endpoint, with consistent improvement in slow vital capacity and lower neurofilament light chain (NfL) [S17]. The ALS/MND international alliance characterised the top-line data as not suggesting a strong clinical benefit [S42].

(b) CS20AT04 (MSC therapy) — lupus nephritis / SLE

Phase 1 safety study (NCT03174587) ran from May 2017 to August 2019; a long-term follow-up (NCT04522505) completed in July 2024 [S23]. The 2024 IR deck lists a lupus programme (coded CE211AT15) as Phase 1 completed [S25]. No Phase 2 start was identified.

(c) CS10BR05 — multiple system atrophy (MSA)

Listed by GlobalData as a Phase 1 programme [S37]. The 2024 IR deck lists an MSA programme (coded CE111BR16) with a Phase 1 plan submitted [S25]. Note: product codes differ between sources.

(d) HYNR-CS-Allo — allogeneic (HLA-haploidentical) bone-marrow MSC

Intrathecal allogeneic MSC therapy under development for MSA, cerebellar ataxia/spinocerebellar ataxia and ALS; Phase 1 per GlobalData [S37].

(e) Earlier-disclosed / exploratory indications

Neuromyelitis optica (NMO) [S38]; anoxic brain injury (ABI) and refractory epilepsy (cited in 2020 broker research) [S36]. The 2024 Korea IR Council report counted seven pipeline programmes including Neuronata-R [S26].

(f) In-licensing (historical)

Non-clinical CRO Division

Service lineDescriptionTarget customerSource
Toxicology studiesGLP general and specialised toxicity studies required for IND submissionsPharma/biotech sponsors[S38]
PharmacokineticsPK analysis and bioanalysisPharma/biotech[S38]
Safety pharmacologyCore battery safety pharmacologyPharma/biotech[S38]
Environmental toxicityEnvironmental/ecotoxicity testingChemical and industrial clients[S38]
Organoid / transcriptomics-based preclinical testingDeveloped with ATG Lifetech (July 2025 partnership)Next-generation therapeutics developers[S4b]
Functional food and cosmetics material testingDiversification beyond pharmaceuticalsFood and cosmetics ingredient developers[S9]
Government projectsNational R&D project testingPublic research programmes[S8]

Pricing: project-based; not publicly disclosed.

Financial Narrative

All figures are K-IFRS consolidated, fiscal years ending 31 December, sourced from DART-derived aggregators [S1][S2][S4][S5] unless stated.

Income statement

Revenue CAGR FY2021–FY2025: approximately −9.6% per year (computed). Margins computed from the rounded figures above.

Ten-year revenue and operating income history

Source: [S2]. The company has recorded operating losses every year since FY2016 [S2][S31].

Trailing-twelve-month trend (quarterly roll)

Source: [S4]. H1-2026 revenue KRW 9.7 bn and operating loss KRW 10.2 bn [S8].

Balance sheet

Source: [S5]. At 31 March 2026: total assets KRW 105.6 bn; current assets KRW 10.9 bn; cash KRW 2.8 bn [S5].

Cash has never exceeded KRW 3 bn at a year-end in the period shown, meaning the company operates hand-to-mouth, funding losses through treasury-share monetisation (2023 EBs, 2024 sales) and, in 2025, a rights offering.

Trend commentary

  1. Revenue then fell for three consecutive years.

  2. CRO cyclicality. Management attributes the CRO decline to the global downturn and a prolonged slump in Korean biotech funding, which reduced outsourced testing orders [S9].

  3. Neuronata-R suspension. Production halted from Q1 2025; the company identified this as the main driver of H1-2025 revenue decline, though product revenue was already small [S10].

  4. Cost structure. Revenue fell below cost of revenue in 2025, meaning negative gross profit; meanwhile R&D and SG&A rose, widening operating losses [S9][S10].

  5. Inflection signal. H1-2026 new CRO orders of KRW 15.2 bn were 69% above H1-2025 (KRW 9.0 bn); management expects revenue recognition to accelerate in H2 2026 [S8].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment

Segment (KRW Bn)H1-2024H1-2025H1-2026

Total revenue

15.511.69.7

Non-clinical CRO revenue

14.911.39.7

Biopharmaceutical (Neuronata-R) revenue

0.60.30.0

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment (%) and Segment Margins & Growth (%)

Metric (%)H1-2024H1-2025H1-2026

CRO share of total revenue

96.197.4100.0

CRO revenue YoY growth

0-24.2-14.2

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

30.246.333.728.820.2

Operating income (KRW Bn)

-10.5-6.0-19.7-22.0-21.2

Net income (KRW Bn)

-5.01.0-17.7-26.3-26.8

Revenue growth YoY (%)

14.753.1-27.3-14.5-29.9

Operating margin (%)

-34.8-13.0-58.5-76.4-105.0

Net margin (%)

-16.62.2-52.5-91.3-132.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement

MetricFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

18.018.122.324.326.430.246.333.728.820.2

Operating income (KRW Bn)

-1.6-5.1-4.0-5.1-7.0-10.5-6.0-19.7-22.0-21.2

Income Statement (TTM-Mar2025–TTM-Mar2026)

MetricTTM-Mar2025TTM-Jun2025TTM-Sep2025TTM-Dec2025TTM-Mar2026

Revenue (KRW Bn)

26.524.820.120.218.4

Operating income (KRW Bn)

-23.4-24.1-25.9-21.2-23.3

Financial Analysis

MetricStatus

Gross profit

Negative in 2025; TTM to Sep 2025 approx. −KRW 4.0 bn (cost of revenue KRW 24.1 bn vs revenue KRW 20.1 bn) [S7].

EPS (basic/diluted)

TTM to Sep 2025: approx. −KRW 291 per share [S7].

Dividends per share

Zero; no dividends paid (dividend yield 0%) [S6]

Balance Sheet

MetricFY2022FY2023FY2024FY2025

Total assets (KRW Bn)

77.178.6117.5112.4

Current assets (KRW Bn)

15.210.715.817.0

Cash and cash equivalents (KRW Bn)

2.12.31.32.3

Additional Balance-sheet Data Point Details

Additional balance-sheet data pointValue

Total liabilities, 31 Dec 2024

KRW 68.9 bn

Total equity, 31 Dec 2024

KRW 48.6 bn

Short-term borrowings, 30 Jun 2024

KRW 3.0 bn

Current portion of long-term borrowings, 30 Jun 2024

KRW 4.2 bn

Accumulated deficit, 30 Jun 2024

KRW 92.3 bn

Cash (incl. other current assets), 30 Jun 2024

KRW 1.9 bn

Cash incl. short-term financial instruments, 30 Sep 2023

KRW 8.0 bn

Goodwill (Chemon)

KRW 3.9 bn, fully impaired in FY2025

Short-term liabilities vs cash (FY2025)

Short-term liabilities exceed cash on hand

Implied book equity, Oct 2026

≈KRW 45 bn (derived: market cap KRW 107.1 bn ÷ P/B 2.37)

Valuation Snapshot

MetricValue

Operating cash flow H1-2025

−KRW 7.8 bn

R&D expense H1-2024

KRW 5.4 bn (34% of revenue)

Treasury share sales 2024

KRW 10.4 bn

Rights offering Nov 2025 (gross)

KRW 26.1 bn; KRW 19.1 bn earmarked for repaying 3rd and 4th series EBs

Dividends paid / buybacks

None paid; no buyback programme identified

Financial Analysis — ROE

RatioValueBasis / Source

ROE

−66.4% (Valueline, Q1-2026 basis) vs −48.2% (StockHub, Oct 2026)

Discrepancy reflects differing periods/equity bases [S4][S6]

P/B

2.37 (Oct 2026); 1.84 (31 Jul 2026)

[S6][S4]

Debt/equity FY2024 (total liabilities/equity)

1.42x (computed: 68.9/48.6)

[S39]

Net debt/EBITDA

Not meaningful (negative EBITDA)

—

Revenue by Region

MetricTTM-Mar2025TTM-Jun2025TTM-Sep2025TTM-Dec2025TTM-Mar2026

Total revenue (KRW Bn)

26.524.820.120.218.4

Domestic revenue (KRW Bn)

26.524.820.220.218.4

Share Price & Returns

DateClose (KRW)

Jan 2023

EB exchange price set at 8,870

13 Oct 2025

1,647

22 Oct 2025

1,680

31 Jul 2026

1,809

~14 Oct 2026

2,025

52-week range (to Oct 2026)

1,014 – 6,100

Valuation Multiples

MultipleCorestemChemonNote

P/E

Not meaningful (losses)

[S6]

P/B

2.37

[S6]

EV/Sales

≈5x (market cap KRW 107 bn / FY2025 revenue KRW 20.2 bn, ignoring net debt)

Computed

Capital Markets

ItemStatus

Analyst consensus

None (zero covering reports)

Dividend history / policy

No dividends

Buyback authorisations

None identified; treasury shares have been sold, not bought

Debt instruments

2nd and 3rd series EBs (Jan 2023, KRW 32.3 bn); 3rd and 4th series repaid with 2025 rights proceeds (KRW 19.1 bn)

Analyst Conclusions

Management guidance (qualitative)

  • FDA Type C meeting expected before end-October 2026; written minutes within 30 days of the meeting [S16].

  • Full-scale Neuronata-R production and treatment resumption in early 2027 [S17].

  • US BLA filing targeted for 2027 [S16][S17].

  • CRO revenue recovery in H2 2026 on conversion of H1 orders [S8].

Consensus growth expectations: none available.

Bull case

  1. Regulatory de-risking in Korea is done. The May 2026 MFDS approval removes the immediate risk of market withdrawal and, with Osong licensed, revenue can restart in 2027 [S17][S15].

  2. CRO is turning. H1-2026 orders rose 69% to KRW 15.2 bn and the in-progress contract book is KRW 27.15 bn; given operating leverage, even moderate revenue recovery would narrow losses materially [S8].

  3. Option value in the US. A constructive Type C outcome on a slow-progressor, NfL-supported label could support RMAT and a 2027 BLA, which would be transformative relative to a ≈KRW 107 bn market cap [S16][S6].

Bear case

  1. The pivotal trial failed. Subgroup and biomarker arguments may not satisfy FDA, and the Relyvrio episode makes regulators cautious [S21][S33].

  2. Funding gap. Year-end cash of KRW 2.3 bn (FY2025) against annual operating losses above KRW 20 bn implies further equity issuance before any US revenue [S5][S2].

  3. Product economics are small. Even at full production, Neuronata-R historically generated around 4% of revenue (≈KRW 1–2 bn per year), raising doubt that Korean sales alone can fund the company [S30][S31].

Catalysts and monitorables (next 12 months)

  1. FDA Type C meeting minutes (expected Q4 2026).

  2. Q3-2026 report (mid-November 2026): CRO revenue conversion and gross margin.

  3. Osong comparability evaluation and production restart timeline.

  4. Any new equity or debt financing.

  5. RMAT application/designation.

  6. FY2026 annual report (March 2027): pre-tax loss vs equity for KOSDAQ listing-maintenance tests.

  7. First foreign-patient treatments in Korea (2027).

Analyst verdict

CorestemChemon is best understood as a distressed CRO carrying a high-risk regulatory option on an ALS cell therapy. The CRO, inherited through the 2022 Chemon merger, generates all current revenue but has shrunk from KRW 46.3 bn in FY2022 to KRW 20.2 bn in FY2025, slipped into negative gross profit, and forced a full write-off of the goodwill created by the merger. The cell-therapy business has produced only marginal revenue historically and none since early 2025, while its pivotal Phase 3 trial missed its primary endpoint in the overall population.

Against that, 2026 has delivered genuine progress. The MFDS kept Neuronata-R on the Korean market after reviewing Phase 3 data, the Osong plant has the licences needed to restart supply, and CRO order intake has recovered sharply. The company has also built credible US scaffolding through NSF/WFIRM membership and a pending FDA Type C meeting.

The central analytical problem is that the two halves of the business do not fund each other. The CRO cannot cover group operating losses of roughly KRW 21 bn a year, and Korean Neuronata-R sales are too small to close the gap. The equity story therefore rests almost entirely on the FDA's response to a post-hoc subgroup argument — an argument regulators have historically treated cautiously, and one sharpened by the Relyvrio withdrawal. Even a constructive meeting is more likely to yield a request for additional confirmatory evidence than a direct path to approval, which would require capital the company does not have.

At roughly 5x trailing sales and 2.4x book with no analyst coverage, the valuation embeds meaningful optionality on the US pathway. The investment profile is binary and financing-dependent: the FDA minutes and the next funding event will determine outcomes far more than operating results.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleNotes

Yang Gil-an (양길안)

Representative Director / Chairman (registered executive)

Listed as representative in 2024 IR and FY2025-based company data; holds 8,757 shares after Oct 2025 rights allotment

Kim Kyung-suk (김경숙)

Founder; largest shareholder (6.49%)

Former CEO of CORESTEM (named CEO in 2018–2020 press); some vendors still list her as CEO — discrepancy flagged

Kwon Kwang-soon (권광순)

President (사장)

Held 0.83–0.93% in specified securities in Oct 2025; subscribed KRW 6.7 bn of the 2023 3rd-series EB

Kim Moon-soon (김문순)

Director (reported as both 이사 and non-registered executive)

0.01%

Gil Ki-hyun (길기현)

Managing Director (non-registered)

0.11%

Ryung-A Lee

Head of R&D Innovation

Presented at PACTALS 2025

Major Shareholders

HolderStake

Kim Kyung-suk (largest shareholder, own stake)

6.49%

Treasury shares

≈4.78%

Kwon Kwang-soon

≈0.14% common shares (0.83% incl. rights, Oct 2025)

Minority shareholders (28,190 holders)

79.25%

Competitive Landscape

Key Competitors

CompetitorProduct / approachStatus (as known)Relative positioning

Mitsubishi Tanabe Pharma

Edaravone (Radicava / Radicava ORS)

Approved in multiple markets

Established standard-of-care adjunct

Riluzole (originator Sanofi; generics)

Glutamate modulator

Approved globally; generic

Baseline therapy

Biogen / Ionis

Tofersen (Qalsody) for SOD1-ALS

FDA accelerated approval 2023 (NfL-based)

Precedent for NfL as a surrogate — relevant to CorestemChemon's argument

Amylyx

Relyvrio

Approved in the US in Sept 2022 on Phase 2 data; withdrawn in 2024 after Phase 3 failure; Korean press cites ≈KRW 550 bn in sales over ~14 months [S33]

Cautionary precedent for approval on weak pivotal data

BrainStorm Cell Therapeutics

NurOwn (autologous MSC-NTF)

US Phase 3 failed primary endpoint (2020) [S36]

Closest cell-therapy analogue

Kadimastem

AstroRx (astrocyte cells)

Early clinical

Former prospective partner [S34]

Key Competitors — Korea Institute of Toxicology

CompetitorProfileData point

Korea Institute of Toxicology (KIT)

Government-funded GLP toxicology institute

—

Biotoxtech (KOSDAQ 086040)

Founded Aug 2000; Cheongju-based non-clinical CRO; AI-assisted pathology

—

DT&CRO (KOSDAQ 383930)

Full-service CRO (efficacy, non-clinical, Phase 1); listed Nov 2022

H1-2025 revenue KRW 20.2 bn (+46% YoY); market cap ≈KRW 34.6 bn (late 2025)

Woojung Bio, CNR Research, Dream CIS

Korean CRO peers (preclinical/clinical)

—

Charles River Laboratories, Inotiv, WuXi AppTec

Global preclinical CROs

—

Peer Comparison FY2025

MetricCorestemChemonDT&CRO

H1-2025 revenue (KRW Bn)

11.620.2

H1-2025 revenue growth YoY (%)

-2546

Company Snapshot

$14.2M

Revenue

391

Employees

2003

Founded

Seongnam, South Korea

Headquarters

SWOT Analysis

Strengths

  • MFDS approved the Neuronata-R license modification in May 2026, preserving the only marketed revenue asset [S17][S1].
  • Over 400 patients treated in Korea, providing long-term safety data [S17].
  • FDA (2018) and EMA (2019) orphan drug designations [S17].
  • Slow-progressor subgroup met CAFS and ALSFRS-R with NfL reductions [S17].
  • Two licensed manufacturing sites (Yongin GMP; Osong with Dec-2025 and May-2026 licences) [S15].
  • CRO backlog of KRW 27.15 bn in-progress contracts at June 2026, with KRW 15.2 bn new orders in H1-2026 [S8].

Weaknesses

  • Phase 3 primary endpoint not met in the overall population [S21].
  • Ten consecutive years of operating losses (FY2016–FY2025) [S2].
  • Revenue fell 56% from the FY2022 peak (KRW 46.3 bn) to FY2025 (KRW 20.2 bn) [S2].
  • Negative gross profit in 2025 [S7][S9].
  • Year-end cash never above KRW 2.3 bn in FY2022–FY2025; short-term liabilities exceed cash [S5][S9].
  • Chemon goodwill fully impaired (KRW 3.9 bn), signalling lower CRO earnings power [S9].

Opportunities

  • FDA Type C meeting could define a BLA pathway; BLA targeted 2027 [S16][S17].
  • Potential RMAT designation [S14].
  • Medical-tourism model: foreign patients treated in Korea from 2027 [S17].
  • NSF/WFIRM ecosystem access in North Carolina [S18].
  • CRO diversification into food/cosmetics materials and organoid-based testing [S9][S4b].
  • Allogeneic platform (HYNR-CS-Allo) could address autologous logistics constraints [S37].

Threats

  • FDA may require a new confirmatory trial rather than accept a post-hoc subgroup analysis (inference from the trial outcome; not a stated FDA position).
  • Relyvrio precedent heightens regulator caution on weak pivotal data [S33].
  • Further dilution: the November 2025 offering exceeded 60% of pre-offering shares [S11].
  • KOSDAQ management-issue designation risk tied to pre-tax losses relative to equity [S11].
  • Competition from larger, faster-growing Korean CROs (e.g., DT&CRO +46% H1-2025) [S40].
  • Manufacturing restart risk at Osong (comparability evaluation) [S14].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
14 May 2025Q1-2025 report filed [S2b]Revenue decline continues
29 May 2025Phase 3 subgroup data: efficacy signals in slow progressors; plans to meet FDA [S19]Re-frames failed trial toward precision positioning
Jul 2025MFDS requests supplementary data on license modification; deadline later extended from 1 Sep to 31 Oct 2025 [S12]Regulatory uncertainty
21 Jul 2025ATG Lifetech partnership (organoid/transcriptomics CRO services) [S4b]CRO diversification
14 Aug 2025H1-2025 report: revenue KRW 11.6 bn (−25%); CRO KRW 11.3 bn (−23%); OCF −KRW 7.8 bn [S10]Confirms cash burn
18 Aug 2025Board approves shareholder rights offering: 20 m shares, expected price KRW 1,890 (≈KRW 37.8 bn) [S13][S12]First equity raise in company history
18 Sep 2025Full ALSummit results presented at PACTALS 2025 (Melbourne) [S20]Scientific disclosure
Sep 2025First issue price set at KRW 1,464 (≈KRW 29.3 bn) [S11]Raise shrinks 22.5%
14–20 Oct 2025Rights certificates trade; insiders file ownership reports [S13][S39]—
20–22 Oct 2025President Kwon Kwang-soon and Director Kim Moon-soon sell portions of rights certificates [S39]Insider signal (modest)
29 Oct 2025Final issue price KRW 1,307; KRW 26.1 bn; KRW 19.1 bn for repaying 3rd/4th EBs [S12]Balance-sheet repair
3–4 Nov 2025Existing-shareholder subscription; company says MFDS review to run to mid-Nov, targeting 2025 decision [S12]Decision slips to 2026
11 / 24 Nov 2025Payment date / new share listing [S13][S5]Share count rises to ≈52.9 m
14 Nov 2025Q3-2025 report filed [S2b]—
Dec 2025Osong plant: advanced biopharmaceutical manufacturing licence change approved [S15]Manufacturing readiness
17 Dec 2025Admission to NSF-backed Piedmont Triad Regenerative Medicine Engine; US operations to move to North Carolina [S18]US positioning
19 Mar 2026FY2025 annual report: revenue KRW 20.2 bn; operating loss KRW 21.2 bn; net loss KRW 26.8 bn; Chemon goodwill KRW 3.9 bn fully impaired [S2][S9]Weakest revenue in a decade
Mar 2026AGM: management says CRO sales rising since Q4-2025 [S9]Recovery narrative
8 Apr 2026Press flags liquidity stress: short-term liabilities exceed cash; Yongin utilisation 1.4% [S9]Going-concern-type risk signal
13 Apr 2026Press notes MFDS decision as make-or-break after 22 years of development [S33]Binary catalyst
22 Apr 2026MFDS central pharmaceutical affairs advisory committee expected to review the case; decision as early as May [S32]Regulatory step
12 May 2026Osong cell processing facility licence obtained [S15]Supply infrastructure complete pending comparability
15 May 2026Q1-2026 report filed [S2b]—
26 May 2026Disclosure: MFDS approves Neuronata-R license modification [S1]Product stays on Korean market
4 Jun 2026Company outlines Osong comparability evaluation, FDA Type C → RMAT → BLA sequence [S14]Execution roadmap
20 Jul 2026PR: approval retained; full-scale production expected early 2027; foreign patients to be treated in Korea; BLA targeted 2027 [S17]Timeline set
4 Aug 2026FDA Type C meeting request filed (9 items); meeting expected before end-October [S16]Near-term catalyst
14 Aug 2026H1-2026 report: revenue KRW 9.7 bn; operating loss KRW 10.2 bn; in-progress contract value KRW 27.15 bn [S8]CRO backlog building
2 Sep 2026H1-2026 new CRO orders KRW 15.2 bn (+69% YoY); recovery continuing into Q3 [S8]Leading indicator improves
Oct 2026Shares trade ≈KRW 2,025; market cap ≈KRW 107 bn; 52-week range KRW 1,014–6,100 [S6]Valuation reference

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment: Total revenue fell from KRW 15,500 Mn in 2024 to KRW 9,700 Mn in 2026.
CORESTEMCHEMON Inc. — Revenue by Segment
Series (KRW Mn)202420252026
Total revenue15,50011,6009,700
Non-clinical CRO revenue14,90011,3009,700
Biopharmaceutical (Neuronata-R) revenue6003000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. S1Butler.works — CorestemChemon company page (financials, disclosures) (butler.works)
  2. S2ETFshopping — 166480 price/financials (FY2016–FY2025) (etfshopping.com)
  3. S2bETFshopping — earnings calendar / periodic filings (etfshopping.com)
  4. S3ETFshopping — company and shareholder data (FY2025 annual report basis) (etfshopping.com)
  5. S4Valueline Korea — income statement / valuation (valueline.co.kr)
  6. S4bPR Newswire Asia — CorestemChemon newsroom (ATG Lifetech, Jul 2025) (en.prnasia.com)
  7. S5Valueline Korea — balance sheet (valueline.co.kr)
  8. S6StockHub — 166480 quote (Oct 2026) (stockhub.kr)
  9. S7Simply Wall St — A166480 (simplywall.st)
  10. S8The Bell / Money Today, 2 Sep 2026 — CRO order recovery (mt.co.kr)
  11. S9IB Tomato, 8 Apr 2026 — CRO weakness, production halt, liquidity (newstomato.com)
  12. S10The Bell / Money Today, 2 Oct 2025 — CRO slump and funding (mt.co.kr)
  13. S11The Bell / Money Today, 2 Oct 2025 — rights offering and pre-tax loss risk (mt.co.kr)
  14. S12The Bell / Money Today, 5 Nov 2025 — MFDS review status; final issue price (mt.co.kr)
  15. S13Digital Today — rights offering disclosure (18 Aug 2025) (digitaltoday.co.kr)
  16. S14Money Today, 4 Jun 2026 — commercial production and US plans (mt.co.kr)
  17. S15The Bell / Money Today, 12 May 2026 — Osong cell processing licence (mt.co.kr)
  18. S16The Bell / Money Today, 4 Aug 2026 — FDA Type C request (mt.co.kr)
  19. S17PR Newswire, 20 Jul 2026 — Neuronata-R retains approval in Korea (kosmo.com.my)
  20. S18PR Newswire, 17 Dec 2025 — NSF-backed US expansion (biospace.com)
  21. S19PR Newswire, 29 May 2025 — Phase 3 subgroup analysis (biospace.com)
  22. S20PR Newswire, Sep 2025 — PACTALS 2025 presentation (taiwannews.com.tw)
  23. S21ALS News Today — Phase 3 final results (alsnewstoday.com)
  24. S22ClinicalTrials.gov — NCT04745299 (ALSummit) (clinicaltrials.gov)
  25. S23ClinicalTrials.gov — NCT03174587 / NCT04522505 (CS20AT04) (clinicaltrials.gov)
  26. S24CorestemChemon IR deck, 25 Sep 2024 (file.alphasquare.co.kr)
  27. S25CorestemChemon IR deck, 20 Jun 2024 (file.alphasquare.co.kr)
  28. S26Korea IR Council research report, 17 Jul 2024 (stock.pstatic.net)
  29. S27Medical Times, 19 Aug 2022 — Chemon absorption (medicaltimes.com)
  30. S28BioSpectator — merger terms (biospectator.com)
  31. S29Smart Today, 18 Jan 2023 — exchangeable bonds (smarttoday.co.kr)
  32. S30Dealsite, 6 Sep 2024 — treasury share sales, liquidity (dealsite.co.kr)
  33. S31IB Tomato, 1 Dec 2023 — losses and liquidity (newstomato.com)
  34. S32Edaily (via Daum), 22 Apr 2026 — MFDS advisory review (v.daum.net)
  35. S33Money Today, 13 Apr 2026 — 22-year development, approval stakes (mt.co.kr)
  36. S34Reuters brief via Stockopedia — Kadimastem MOU (stockopedia.com)
  37. S35Dealsite — FDA expanded-access approval (MGH) (dealsite.co.kr)
  38. S36SK Securities research notes (Mar 2020, Dec 2020) (file.alphasquare.co.kr)
  39. S37GlobalData / Pharmaceutical Technology — HYNR-CS-Allo (pharmaceutical-technology.com)
  40. S38AeroLeads — CorestemChemon company overview (aeroleads.com)
  41. S39Digital Today AI disclosures — insider ownership reports (Oct 2025) (digitaltoday.co.kr)
  42. S40Kiwoom Securities — DT&CRO report (2025) (bbn.kiwoom.com)
  43. S40bTHE VC — Biotoxtech / DT&CRO profiles (thevc.kr)
  44. S42International Alliance of ALS/MND Associations — Neuronata-R profile (als-mnd.org)
  45. S43Medical Times, 14 Nov 2018 — Q3-2018 results (medicaltimes.com)

Data gaps flagged for DART follow-up: FY2021–FY2025 cash flow statements, FY2025 liabilities/debt split, annual segment revenue and segment operating income, annual R&D expense, auditor, board composition and executive compensation, ISIN, patent count, and the FY2025 large-holding report filer.

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.